Search by Title Article Topic - Any -AdvocacyCertificationClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure AwarenessHeart Failure GuidelinesHFSA Annual Scientific MeetingHFSA AwardsHFSA Board Certification ReviewHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterHFSA MembershipIn The NewsIndustryJournal of Cardiac FailureMentorshipNursingPartnersPatient ResourcePodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News May 6 2021 | FARXIGA approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes Industry News Industry Read More Mar 24 2021 | U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Industry News In The News Industry Read More Feb 19 2021 | Novartis Entresto® granted expanded indication in chronic heart failure by FDA Industry News Industry Read More Jan 22 2021 | Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) Industry News Industry Read More Jan 13 2021 | US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction Industry News In The News Industry Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page Next › Last page Last »
May 6 2021 | FARXIGA approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes Industry News Industry Read More
Mar 24 2021 | U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Industry News In The News Industry Read More
Feb 19 2021 | Novartis Entresto® granted expanded indication in chronic heart failure by FDA Industry News Industry Read More
Jan 22 2021 | Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) Industry News Industry Read More
Jan 13 2021 | US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction Industry News In The News Industry Read More
